CALL/VERTEX PHARMACEUTICALS/700/0.1/17.01.25 | Real-time BOERSE MUENCHEN 02:26:58 2024-06-26 pm EDT | ||
| 0.266 EUR | -2.21% |
|
| Current month | +33.33% | ||
| 1 month | +86.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 0.266 | -2.21% |
| 24-06-25 | 0.272 | +2.26% |
| 24-06-24 | 0.266 | +0.76% |
| 24-06-21 | 0.264 | -25.00% |
| 24-06-20 | 0.352 | +23.51% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 02:26 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG19SU |
| ISIN | DE000GG19SU9 |
| Date issued | 2023-12-18 |
| Strike | 700 $ |
| Maturity | 2025-01-17 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 0.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.574 € |
|---|---|
| Lowest since issue | 0.067 € |
| Spread | 0.3 € |
| Spread % | 56.60% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Warrants
- Warrant
